Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29186500 | 0.85 | DYRK1A (0.46) | DYRK1AHPGDMEN1KMT2ACCNA2 | |
| SCHEMBL31307034 | 0.80 | DYRK1A (0.42) | DYRK1AHPGDMEN1KMT2ACCNA2 | |
| SCHEMBL1555895 | 0.77 | DYRK1A (0.43) | DYRK1AHPGDMEN1KMT2ARAB9A | |
| SCHEMBL27599943 | 0.74 | HPGD (0.41) | DYRK1AHPGDMEN1KMT2ACDK2 | |
| SCHEMBL26820 | 0.73 | HPGD (0.54) | HPGD | |
| SCHEMBL2359207 | 0.72 | HPGD (0.43) | DYRK1AHPGDMEN1KMT2ACDK2 | |
| Hydrochloric Acid SCHEMBL27727584 | 0.71 | HPGD (0.52) | HPGD | |
| SCHEMBL17645589 | 0.71 | CCNA2 (0.44) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL2544544 | 0.70 | — | — | |
| SCHEMBL27725626 | 0.69 | HPGD (0.40) | DYRK1AHPGDMEN1KMT2ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131669-B2 | Pyrazolopyrimidine compounds | PFIZER INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| WO-2017027984-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CANCER BY INHIBITING ATG4B AND BLOCKING AUTOPHAGY | SIMON FRASER UNIVERSITY (CA) | 2017-02-23 | — | — | WO | disclosed |
| US-9388181-B2 | Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160096837-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131669-B2 | Pyrazolopyrimidine compounds | PDE4B, PDE4A, PDE7A | DYRK1A 1064/4885HPGD 954/4885MEN1 4159/4885 |
| US-20160096837-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS | TK1, CDK2, MAP4K2 | DYRK1A 432/4885HPGD 2085/4885MEN1 3922/4885 |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | DPYD, QDPR, ABCG2 | DYRK1A 2288/4885HPGD 1926/4885MEN1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.